SCHEMBL20111310

SCHEMBL20111310

Cc1ccc(COc2ccc3c(c2F)-c2c-3cc(O)c(F)c2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.42
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
RECQL P46063 2/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GAA P10253 1/20 0.38
MAOB P27338 2/20 0.38
MAPK1 P28482 2/20 0.37
PTGER1 P34995 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20117611 0.84 GAA (0.46) FFAR4NPC1RAB9ACYP1A2CYP2C19
SCHEMBL20111651 0.80 FGFR2 (0.38) NPC1RAB9AALDH1A1SMN1; SMN2MEN1
SCHEMBL20111697 0.74 PTGS2 (0.39) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL20102522 0.73 SMPD1 (0.41) FFAR4LMNAMAPTALDH1A1CYP3A4
SCHEMBL20111640 0.72 HTR1A (0.45) NPC1RAB9ALMNAMAPTALDH1A1
SCHEMBL24234157 0.72 NPC1 (0.49) NPC1RAB9ACYP1A2CYP2C19RECQL
SCHEMBL17433295 0.70 GAA (0.43) FFAR4NPC1RAB9ACYP1A2CYP2C19
SCHEMBL10091327 0.70 MAPT (0.55) FFAR4NPC1CYP1A2CYP2C19LMNA
SCHEMBL20102464 0.70 SMPD1 (0.41) RAB9ALMNAMAPTALDH1A1CYP3A4
SCHEMBL12736499 0.70 FFAR4 (0.48) FFAR4NPC1RAB9ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S FFAR4 309/4885NPC1 1740/4885RAB9A 2259/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S FFAR4 309/4885NPC1 1740/4885RAB9A 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.